Vancomycin
Vancomyzer™
Bayesian AUC-guided vancomycin dosing for adults on intermittent IV therapy. Free for individual clinicians; no account needed. Independent clinical validation is pending.
What it shows
A real screen, from a synthetic case.
Vancomyzer walkthrough · 2:17
How it calculates
One model for every adult.
The Colin 2019 two-compartment population model gives a starting estimate from age, weight and serum creatinine. It is a pooled analysis of 14 studies (2,554 individuals) and is used for every adult, at every body size. With one or two measured levels, a Bayesian fit adjusts the estimate toward the patient’s data; the adjustment is bounded, so one unusual level cannot override the population data.
Targets follow the 2020 ASHP/IDSA/PIDS/SIDP consensus guideline (AUC₂₄ 400–600 mg·h/L), which recommends AUC-guided monitoring, preferably with Bayesian estimation. The guideline is not an endorsement of any product.
The equations, the fitting settings, and every check run so far are published on vancomyzer.com/transparent-dosing.
Built-in checks
Applied to every estimate.
- Recommendations are withheld for patients on dialysis or other renal replacement therapy.
- Infusions are capped at 10 mg/min and at least 60 minutes.
- No dose below 500 mg is offered.
- Advisories for age over 65, bedbound patients, a BMI of 40 or more, questionable level timing, and a poor fit to measured levels.
Evidence status
What has been checked, by whom, and what has not.
| Item | What it covers | Status |
|---|---|---|
| Population model | Colin 2019 two-compartment model; equations and references published | Published |
| Literature reproducibility | Published vancomycin cases run through the calculator; same-model cases are pass/fail | Developer-run |
| Predictive performance | Synthetic ICU patients from a different published model; not real patients | Developer-run |
| Comparison with Tucuxi | Same prior and simulated levels given to a separately built program, scored against pre-set criteria | Developer-run |
| Independent clinical validation | Study with patient data at a participating institution | Pending |
“Developer-run” identifies checks designed and performed by the software’s author using published values or simulated patients. These are not independent clinical validation and no claim is made that Vancomyzer improves patient outcomes.
Scope and access
Who it is for, and how to access it.
Designed for
Clinical pharmacists, infectious diseases teams and stewardship programs. Adults (18 years and older) receiving intermittent IV vancomycin.
Not designed for
Pediatric patients, patients on dialysis or other renal replacement therapy, and continuous-infusion vancomycin.
Access to Vancomyzer is currently free.
Saved history and institutional features remain restricted and are not currently available for new access requests. You may register your interest using the access-request topic.
Request restricted accessOpen the calculatorVancomyzer™ is a clinical decision-support tool for qualified healthcare professionals only. Not FDA-cleared or approved. Designed to meet the non-device clinical decision support criteria of FD&C Act §520(o)(1)(E); not reviewed by the FDA. Calculations run on a server; enter no patient identifiers. See the privacy policy.